The margination of polymorphonuclear leucocytes (PMNs) in microvessels and their migration out of the vascular space is a multistep process that is regulated by a cascade of molecular events involving several families of adhesion proteins. Adams and Shaw' have recently reviewed the evidence for the hypothesis that this process begins with a selectin-mediated rolling of the PMNs on the endothelial surface of the post-capillary venules followed by a chemokine-induced triggering of a stronger, integrinmediated adherence between the leucocyte and the endothelial surface that occurs in preparation for migration. The data that support this hypothesis are impressive, particularly for the systemic vessels where both margination and migration apparently occur in post-capillary venules.
However, in the pulmonary circulation there are compelling reasons to believe that the circulating cells slow down, adhere, and migrate through the endothelium of the capillaries, and that only a fraction of the PMNs passing through an inflammatory site become significantly activated to migrate out of the vascular space.2
The progressive activation of PMNs is most easily investigated in vitro. Studies using a prototypic agonist of neutrophils, f-met-leu-phe (FMLP), have shown that low concentrations (10-1210-10M) are associated with reorganisation of the cytoskeleton to a configuration which allows the cells to move independently.3 As the FMLP concentration is increased, the specific granules release CD1Ib/CD18 onto the surface and L-selectin is shed.6
These events occur in association with increased intracellular levels of inositol trisphosphate and calcium.7
However, it is only at very high concentrations (10-710-6 M) that the major cytotoxic responses of azurophilic granule release and superoxide production are demonstrable.6 Other agonists that use structurally similar receptors (interleukin 8, platelet aggregating factor, C5a) have similar dose-dependent responses but these agonists can also prime the cell and amplify its cytotoxic response.89
Priming refers to an enhanced response that results from the sequential addition of priming agent and agonist.9
Priming of the superoxide response usually occurs at intermediate doses sufficient to cause increases in intracellular calcium and specific granule release, but just at or below the doses necessary to release superoxide.89 Other mediators such as the cytokines (interleukin 1, granulolytemacrophage colony stimulating factor, tumour necrosis factor) and endotoxin are incapable of producing a full repertoire of neutrophil responses.
The relationship between the graded neutrophil response in vitro and their behaviour in vivo has only been partially determined. Their response within the vascular space where agonist concentrations are low is probably limited to the assembly of actin, a reduction in cell deformability, upregulation of CD 1lb/CD 18, and a loss of L-selectin from the cell surface. Once adherent to the endothelium, the cells move along chemotactic or haptotactic gradients centred at the site of injury. This allows the PMNs to encounter increasing agonist concentrations that first prime and then trigger a full cytotoxic response. Any abnormality in this sequence that allows large numbers of PMNs to become fully activated before leaving the vascular space puts the lung tissue itself at risk of injury.
Approximately 8640 litres of blood pass through the pulmonary circulation of an adult human in 24 hours. As 
